Unknown PHASE1 INTERVENTIONAL 1-arm NCT03815383

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma

Sponsor: The First Affiliated Hospital with Nanjing Medical University

Conditions Relapsed or Refractory Multiple Myeloma

Interventions C-CAR088

Updated 6 times since 2019 Last updated: Jul 1, 2019 Started: Apr 11, 2019 Primary completion: Jan 31, 2021 Completion: Apr 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Relapsed or Refractory Multiple Myeloma, this trial is ongoing. The trial is conducted by The First Affiliated Hospital with Nanjing Medical University and has accumulated 6 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE1
Aug 2019 — Jan 2021 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Feb 2019 — Aug 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The First Affiliated Hospital with Nanjing Medical University

Data source: The First Affiliated Hospital with Nanjing Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanjing, China